Emergency reversal of dabigatran for emergency surgery

BMJ Case Reports

Volumn 2015, Issue , 2015, Pages

  Puttick, Thomas ^a   Bahl, Rahul ^a   Mohamedbhai, Hussein ^a  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMILORIDE PLUS FUROSEMIDE; BISOPROLOL; DABIGATRAN ETEXILATE; FUROSEMIDE; LACTIC ACID; RAMIPRIL; SIMVASTATIN; VITAMIN K GROUP; ANTITHROMBIN; BLOOD CLOTTING FACTOR; DABIGATRAN;

AGED; ANTICOAGULATION; ATRIAL FIBRILLATION; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; EMERGENCY SURGERY; EVENING DOSAGE; FEMALE; FEMORAL HERNIA; HERNIA INCARCERATION; HIP ARTHROPLASTY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LACTATE BLOOD LEVEL; MEDICAL HISTORY; OPERATIVE BLOOD LOSS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; THROMBIN TIME; VERY ELDERLY; EMERGENCY MEDICINE; HERNIA, FEMORAL; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION FACTORS; DABIGATRAN; EMERGENCY MEDICINE; FEMALE; HERNIA, FEMORAL; HUMANS; INTERNATIONAL NORMALIZED RATIO; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME;

EID: 84929590926     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2014-209057     Document Type: Review

References (16)

1. Kaatz S, Crowther M. Reversal of target-specific oral anticoagulants. J Thromb Thrombolysis 2013;36:195-202.
2. Thomas K. A promising drug with a flaw. The New York Times 2 November 2012.
3. Jones C, Pollit V, Fitzmaurice D, et al. The management of atrial fibrillation: summary of updated NICE guidance. BMJ 2014;348:g3655.
4. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation An update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
6. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ 2014;349:g4670.
7. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43:1511-17.
8. Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 2013;31:163-8.
9. Kaatz S, Kouides PA, Garcia DA, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 2012;87(Suppl 1):S141-5.
10. van Ryn J, Schurer J, Kink-Eiband M, et al. The successful reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation. Blood (ASH Annual Meeting Abstracts) 2011;118:2316.
11. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost 2012;10:1841-8.
12. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013;41:e42-6.
13. Chiew A, Khamoudes D, Chan B. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clin Toxicol (Phila) 2014;52:283-7.
14. Schiele F, van Ryn J, Newsome C, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121:3554-62.
15. Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2012;159:427-9.
16. Wong H, Keeling D. Activated prothrombin complex concentrate for the prevention of dabigatran- associated bleeding. Br J Haematol 2014;166:152-3.